Alphagan : Patient Homepage

How does glaucoma affect your eyes?

Your eyes naturally contain fluid called aqueous humor, which keeps them nourished and healthy. Normally, this fluid flows and drains freely. In patients with glaucoma, the fluid does not drain properly. This buildup of fluid causes increased pressure inside the eye and is referred to as elevated intraocular pressure, or IOP. If IOP remains elevated, it can permanently damage the optic nerve and impair your vision.

Though there is no cure for glaucoma, reducing elevated IOP is the only treatable glaucoma risk factor to prevent vision loss. Studies show that IOP-lowering medications can delay or prevent the development of glaucoma and its associated vision loss.^1-3

ALPHAGAN^® P ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Important Safety Information
ALPHAGAN^® P (brimonidine tartrate ophthalmic solution) 0.1% should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, ocular redness, and itching. Adverse events occurring in approximately 5% to 9% included: burning sensation, increased ocular lymph nodules, increased ocular pressure, ocular allergic reaction, dry mouth, and blurred vision.

Please click here for full Prescribing Information.

^{1. The AGIS Investigators. The Advanced Glaucoma Invervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130(4):429-440. 2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279. 3. Kass MA, Heuer DK, Higginbotham EJ, et al, for the Ocular Hypertension Treatment Study Group. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.}